Filtered By:
Condition: Heart Failure
Drug: Clopidogrel
Education: Study

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 34 results found since Jan 2013.

Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health.
CONCLUSION: Ticagrelor significantly reduced the risk of MACE than clopidogrel for AMI patients with MVD in Korea. However, the risk of TIMI major or minor bleeding was higher and the net clinical benefit was similar. Further large-scale multi-center randomized clinical trials are needed to clarify the proper use dual antiplatelet therapy in East Asian populations. PMID: 31859138 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - December 15, 2019 Category: Cardiology Authors: Ahn JH, Ahn Y, Jeong MH, Kim JH, Hong YJ, Sim DS, Kim MC, Hwang JY, Yoon JH, Seong IW, Hur SH, Oh SK, other KAMIR-NIH Registry Investigators Tags: J Cardiol Source Type: research

Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
ConclusionsIn patients who receive clopidogrel after PCI, concomitant use of PPI seems to increase the risk of major cardiovascular events.
Source: Cardiovascular Drugs and Therapy - November 11, 2022 Category: Cardiology Source Type: research

Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score-Matched Cohort Study
The objective of this study was to evaluate cardiovascular events based on ticagrelor, prasugrel, and clopidogrel use in a real-world patient setting. This retrospective cohort study used the IBM MarketScan database (January 1st, 2013, to December 31st, 2018) to create 3 propensity score-matched pairs: ticagrelor vs. clopidogrel (N=21,719), prasugrel vs. clopidogrel (N=11,513), and prasugrel vs. ticagrelor (N=11,065). The primary outcome was a composite of myocardial ischemia, unstable angina, stroke, and heart failure hospitalization. These groups were compared in a time-to-event analysis for the primary outcome at 30, 90...
Source: Clinical Pharmacology and Therapeutics - November 18, 2022 Category: Drugs & Pharmacology Authors: Arun Kumar Pamela L Lutsey Wendy L St Peter Jon C Schommer Jeremy R Van't Hof Abhijeet Rajpurohit Joel F Farley Source Type: research